. s t u d i e s were performed to evaluate glucose homeostasis i n children with i n t r a h e p a t i c b i l i a r y hypoplasia (IBH) with chronic c h o l e s t a t i c syndrome and growth retardation. Eight I.V. glucagon tolerance t e s t s (30 pg/kg) on f i v e IBH p a t i e n t s (4-12 y r s of age) were compared to 8 controls.
Fasting (14-16 h r ) glucose was lower i n I B H (67 + 4 mg% vs 80.8 + 3.67; p (0.025).
and peak r i s e was signifTcantly l e s s (107 + 10.6 vs 147 + 7.9; p < 0.01). Baseline urinary c y c l i c A M P l e v e l s i n IBH 7 s controls (5.8 + 2 M + S.E.M. moles/mg c r e a t i n i n e vs 4.5 + 0.4) and 2 hour excretion response to glucagon (31.1 + 3 vs 28.6 t 5.2) were not s i g n i f i c a n t l y d i f f e r e n t . I n s u l i n response to glucagon were similar i n I B H vs control. Glucagon has previously been shown to lower plasma gluconeogenic amino acids as a indication of hepatic uptake and gluconeogenesis. Fasting plasma alanine was not s i g n i f i c a n t l y d i f f e r e n t i n IBH vs control (210 + 38 umoles/l vs 245 + 40).
Controls had a s i g n i f i c a n t d e l t a decline a t 30 minutes postglucagon of 100 umoles/~ f o r alanine, 66 f o r glycine and 39 f o r g l u t m i n e plus asparagine. IBH p a t i e n t s f a i l e d to e l i c i t a c o n s i s t e n t reduction i n gluconeogenic amino acids. These s t u d i e s suggest t h a t hepatic gluconeogenesis and glycogen storage a r e impaired i n chronic l i v e r disease. The noted c y c l i c A M P response may r e f l e c t adequate adenyl cyclase a c t i v i t y i n s p i t e of hepatocellular damage. Inappropriate plasma glucagon responses t o oral glucose have been reported i n diabetes (DM), and i t has been suggested t h a t alpha c e l l dysfunction i s a characteristic o f genetic DM. To f u r t h e r evaluate t h i s hypothesis, plasma glucagon and i n s u l i n were measured i n children w i t h CF f o llowing standard o r a l glucose (GTT) o r intravenous arginine (ATT) tolerance tests. CF patients were c l a s s i f i e d as being normal (Group A) o r variably abnormal (Group B) on the basis of the glucose responses t o the GTT. During the GTT plasma glucagon declined by a mean o f 64 + 22 pglml i n A (p < 0.05) and by 34 5 7 pglml i n B (p < 0.01r, (A vs. B ns.) while plasma i n s u l i n s peaked a t a mean o f 28 5 5 pU/ml i n A and 4 8 5 1 5 uU/ml i n 8. The ATT resulted i n a s i g n i f i c a n t l y greater glucagon response a t 30 min. i n A than B, 622 + 39 pglml vs. 238 2 74 pglml ( p < 0.005); while the peak i n s u l i n responses were low i n both groups, 13 5 2.6 vs. 21 5 2.2 ~U l m l . These data suggest (1) suppressibili t y o f glucagon t o glucose persists despite carbohydrate intolerance i n CF patients i n contrast t o reported non-suppressibility i n genetic DM. (2) I n s u l i n responsiveness i s obtunded i n CF ' patients i n both groups. (3) CF a f f e c t s pancreatic alpha and beta c e l l function as well as exocrine function. growth occurs with such d i e t a r y optimum. This acceleration r e q u i r e s appropriate changes i n d i e t a r y phenylalanine and c a l o r i e s . J ow serum phenylalanine concentrations ((2 xg/100 ml) indicate increased phenylalanine requirement but increased c a l o r i c n e~d s a r e harder t o determine. Of 19 i n f a n t s xsith PKIT, i d e n t i f i e d by neonatal screening and t r e a t e d by phenylalanine r e s t r i c t i o n since January 1967, 15 excreted increased amo>unts of urinary aTino acids, usually glycine, alanine, methionine and phenylalanine, but occasionally o t h e r s a s rvell. Unappeased appetite, deceleration i n head circumferer,ce change,and aminoa c i d u r i a were usually corrected by increasing d i e t a r y phenylalanine.
Tn sane cases, when the serum pherylalanine was high, improvement i n these c r i t e r i a was acconplished by increasing d i e t a r y c a l o r i e s without increasing phenylalanine intake. Diet p r e s c r i p t i o n s during t h e f i r s t 3 moriths required phenylalanine increases t o a s high a s 125 mg/kg body vrt. and c a l o r i e s t o a s high a s lE5/kg. P.ppropriate decreases were possible a f t e r 4 t o 6 months and allowances per ur.it body wt. vere usually s t a b l e a f t e r 1 year. Aminoaciduria appeared t o r e f l e c t an iqproper d i e t a r y balance.
BENEFIT OF VIGOROUS ANTICEREBRAL EDEMA THERAPY IN REYES SYN-DROME -PROSPECTIVE STUDY. C. K. Lovejoy, A. L. Smith, M. zesnan and C. Lombroso ( I n t r . by David H. Smith) Children's Hos p i t a 1 Medical Center, Dept. of Med., Boston, Mass.
Our previous s t u d i e s (1968-1971) have allowed i d e n t i f i c a t i o n of f i v e c l i n i c a l stages i n p a t i e n t s with Reyes Syndrome based on t h e degree of c e n t r a l nervous system involvement. A l l p a t i e n t s with an i l l n e s s limited t o stages I t o I11 lived;
while those with disease progressing t o stage I V had been associated with a poor outcome (two of 19 lived, both severely im paired neurologically). Stage IV disease, occurred i n 10 of 15 p a t i e n t s followed prospectively (1971) (1972) (1973) . Intensive therapy t o combat c e r e b r a l edema (mannitol i n doses up t o 6g/kg/day, glycerol 6g/kg/day, dexamethazone a t O.Smg/kg/day and f l u i d r e s t r i c t i o n t o 40ml/kg/day) permitted survival i n four of s i x stage I V p a t i e n t s . This i s i n c o n t r a s t t o death occurring i n t h r e e of four stage I V p a t i e n t s t r e a t e d with conventional a n t icerebral edema therapy. C l i n i c a l symptomology (usually a rev e r s a l t o an improved stage) and EEG s t a t u s improved within hours of viqorous therapy. I n these f i v e survivors of s t a g e I V disease; t h r e e ' a r e normal 2 t o 22 months following onset of i l l n e s s ; one has mild hemiparesis and memory d e f i c i t , and one with severe neurologic impairment (hemiballisimus and hemipar e s i s ) i s gradually improving. Intensive therapy d i r e c t e d towards decreasing i n t r a c r a n i a l pressure has allowed survival of children with stage IV Reyes Syndrome. GENERALIZED LIPODYSTR0PHY:EFFECT OF CEREBRAL DOPAMINERGIC BLOCKING AGENT (PIMOZIDE). C . C . Mabry, G.V. Upton, A. Corbin, D.R. Hollingsworth, Univ. Kentucky Col. Med., Lexington, Yale Univ. Sch. Med., New Haven, and Wyeth Lab., Philadelphia.
Generalized lipodystrophy (GLD) , characterized by-l o s s of subcutaneous and other f a t , skeletallmuscle overgrowth, neutral f a t hepatomegaly, g e n i t a l enlargement, gonadal f a i l u r e , hyperpigmentation, acanthosis nigricans, hyperlipidemia, hyperglycemia, and hyperinsulinism, i s associated with detectable hypthalamic regulatory hormones in plasma (J Pediat 82:625, 1973) .
Reasoning t h a t GLD i s a disorder of hypothalamic dysfunction dependent on catecholaminergic mechanisms, and using our e a r l i e r experience with chlorpromazine, we administered Pimozide t o a 7-year-old g i r l with GLD (8 mglday f o r 16 mo). Pimozide (a diphenylbutylpiperidine used as a neuroleptic) i s a s e l e c t i v e i n h i b i t o r of cerebral dopaminergic receptors.
Effects over 16-months were: a ) inunediate and sustained diminution of l u t e i n i z i n g releasing hormone and corticotropin releasing hormone t o zero or trace plasma l e v e l s , b) return of normal response t o intravenous ACTH (Acta Endocr 73:437, 1973) , c ) return of l i v e r function and s i z e t o normal or near nonnal with abatement of abdominal pain, d) reversal of skin and h a i r changes, e ) return of subcutaneous f a t t o face and back a s shown by appearance and biopsy (0.5 cm thick).
These r e s u l t s 1) support the concept of diencephalic involvement in GLD, 2) indicate that Pimozide impairs the synt h e s i s l r e l e a s e of hypothalamic regulatory hormones, and 3) suggest that GLD i s amenable to meaningful treatment.
GLYCEROL INTOLERANCE:
A N E W SYNDROME. Noel K. Maclaren, Carolyn Cowles, Pinar Ozand and Marvin Cornblath, Univ. of Maryland Sch. of Med., Dept. Ped., Baltimore.
A 3 y r old boy had numerous episodes of f a t i g u e , i r r i t ab i l i t y , p a l l o r and sweating dating from 11 mo.of age when he had an episode of symptomatic hypoglycemia with ketonuria. His height and weight were below the 3rd percentile. No hepatomegaly o r c a t a r a c t s were found. I n t e l l e c t u a l development, l i v e r and renal functions, e l e c t r o l y t e s , Tq, hGH and c o r t i s o l values were normal. He manifested euphoria, mental confusion, drowsiness, nausea and vomiting 1-5 h r s a f t e r o r a l glycerol i n doses of 0.5-1 gmlkg. Oral medium chain t r iglycerides ( 1 gmlkg) had s i m i l a r e f f e c t s . Once, o r a l glycero l ( 1 gmlkg) a l s o provoked hypoglycemia with a decline i n blood l a c t a t e . A 16 112 h r f a s t a l s o induced hypoglycemia, unresponsive t o glucagon. IV glycerol (0.09 gmlkg) induced an immediate l o s s of consciousness with no change i n blood glucose. He recovered spontaneously a f t e r 30 min. I V fructose (0.25 @/kg) was t o l e r a t e d normally. Leukocytes showed normal activit:, f o r fructose-1, 6-diphosphatase, glycerol kinase and glycerol phosphate dehydrogenase. However, plasma dopamine 6 hydroxylase a c t i v i t i e s were low and f e l l s i g n i f i c a n t l y following I V o r o r a l glycerol. The r e s t r i c t i o n of d i e t a r y f a t intake improved h i s physical and mental a c t i v i t i e s . These observations suggest a unique, y e t undefined metabolic intolerance t o glycerol. Supported by grants from t h e John A. Hartford Foundation and N I H #HD 03959-06 and HD 06291-03.
